Vericiguat, new backbone for the treatment of heart failure with reduced ejection fraction
DOI:
https://doi.org/10.32818/reccmi.a8n3a2Keywords:
heart failure with reduced ejection fraction, HFrEF, hospitalization, vericiguatAbstract
Heart failure with reduced ejection fraction (HFrEF) is associated with high morbidity and mortality, conditioned by multiple hospitalizations. Vericiguat has currently been
shown to be effective and safe in patients with a recent decompensation. We present a series of three cases using vericiguat in different clinical scenarios: an elderly patient with dilated cardiomyopathy of ischemic origin, a patient with alcoholic cardiomyopathy and polyvalvular heart disease, and a young patient with idiopathic cardiomyopathy. In the 3 cases vericiguat was effective and safe. This medication has been tested and monitored in other studies and we consider it plays an important role in the therapeutic armamentarium of this population, although it is necessary to accumulate more clinical experience.
Downloads
Metrics
References
Maggioni AP. Epidemiology of heart failure in Europe. Heart Fail Clin. 2015; 11(4): 625-635. doi: https://doi.org/10.1016/j.hfc.2015.07.015 (último acceso sept. 2023). DOI: https://doi.org/10.1016/j.hfc.2015.07.015
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernández AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382(20): 1883-1893. doi: https://doi.org/10.1056/NEJMoa1915928 (último acceso sept. 2023). DOI: https://doi.org/10.1056/NEJMoa1915928
Adamo M, Fiorelli F, Melica B, D'Ortona R, Lupi L, Giannini C, et al. COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation. JACC Cardiovasc Interv. 2021; 14(1): 15-25. doi: https://doi.org/10.1016/j.jcin.2020.09.050 (ultimo acceso sept. 2023). DOI: https://doi.org/10.1016/j.jcin.2020.09.050
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-3726. doi: https://doi.org/10.1093/eurheartj/ehab368 (último acceso sept. 2023). DOI: https://doi.org/10.1093/eurheartj/ehab368
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18): e876-e894. doi: https://doi.org/10.1161/CIR.0000000000001062 (último acceso sept. 2023). DOI: https://doi.org/10.1161/CIR.0000000000001073
Wang L, Zhu L, Wu Y, Li Q, Liu H. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis. Ann Palliat Med. 2021; 10(10): 11117-11128. doi: https://doi.org/10.21037/apm-21-2656 (último acceso sept. 2023). DOI: https://doi.org/10.21037/apm-21-2656
Hulot JS, Trochu JN, Donal E, Galinier M, Logeart D, De Groote P, Juillière Y. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opin Pharmacother. 2021; 22(14): 1847-1855. doi: https://doi.org/10.1080/14656566.2021.1937121 (último acceso sept. 2023). DOI: https://doi.org/10.1080/14656566.2021.1937121
Senni M, Alemayehu WG, Sim D, Edelmann F, Butler J, Ezekowitz J, et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. Eur J Heart Fail. 2022; 24(9): 1614-1622. doi: https://doi.org/10.1002/ejhf.2608 (último acceso sept. 2023). DOI: https://doi.org/10.1002/ejhf.2608
Rao VN, Díez J, Gustafsson F, Mentz RJ, Senni M, Jankowska EA, Bauersachs J. Practical patient care considerations with use of vericiguat after worsening heart failure events. J Card Fail. 2023; 29(3): 389-402. doi: https://doi.org/10.1016/j.cardfail.2022.10.431 (último acceso sept. 2023). DOI: https://doi.org/10.1016/j.cardfail.2022.10.431
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Francisco Javier Soria-Romero, Miguel Ángel Pérez-Velasco, Alicia Trenas, José M. Pérez-Ruiz, Luis Miguel Pérez-Belmonte
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
